Nuvation Bio
NUVB
4.86
-0.02
-0.41%
Nuvation Bio
US · NUVB
#2898 by market cap
Listed 1970
4.86
-0.02
-0.41%
Live - 5344 symbols - heartbeat 445s ago
· 2026-10-08 07:33
Pre-market
4.80
-1.23%
After-hours
4.95
+1.85%
Overnight
4.82
-0.82%
- Market cap
- 1.71B
- P/E (TTM)i
- -11.05
- P/Bi
- 6.72
- EPSi
- -0.60
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on NUVB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 67.05% -0.13pp
- Institutions
- 284 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund43.31%
Individual/Insider17.52%
VC/PE Fund10.16%
Hedge Fund8.62%
Public Company2.07%
Family Office/Trust1.35%
Private Company1.11%
Government Pension Fund0.36%
Other15.43%
Top holders as of 2025-06-16
David Hung
17.17% · 60.28M sh
FMR
14.88% · 52.23M sh
BlackRock
7.87% · 27.63M sh
Decheng Capital LLC
7.39% · 25.95M sh
Vanguard Capital Management, LLC
3.90% · 13.70M sh
Omega Fund Management, LLC
2.30% · 8.08M sh
Laurion Capital Management LP
2.23% · 7.82M sh
State Street Global Advisors
2.10% · 7.37M sh
Geode Capital Management, LLC
1.78% · 6.24M sh
Duquesne Family Office LLC
1.29% · 4.54M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| David Hung | Chief Executive Officer | 17.17% |
| William Vernon | Independent Director | 0.09% |
| Kathryn Falberg | Independent Director | 0.07% |
| Robert Mashal | Director | 0.06% |
| Kim Blickenstaff | Independent Director | 0.05% |
| Colleen Sjogren | Chief Commercial Officer | 0.02% |
| Philippe Sauvage | Chief Financial Officer | 0.02% |
| Kerry Wentworth | Chief Regulatory Officer | 0.02% |
| Stacy Markel | Chief Human Resources Officer | 0.01% |
| David Hanley | Chief Technical Operations Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-18 | Gary Hattersley | Chief Scientific Officer | Derivative Exercise and Sale | -100,000 | $1.87–7.09 |
| 2026-07-14 | Philippe Sauvage | Chief Financial Officer | Derivative Exercise and Retained | +40,000 | $1.97–2.17 |
| 2026-06-22 | Kerry Wentworth | Chief Regulatory Officer | Derivative Exercise and Sale | -63,000 | $2.93–6.02 |
| 2026-06-22 | Stacy Markel | Chief Human Resources Officer | Derivative Exercise and Sale | -125,000 | $1.74–6.03 |
| 2026-06-22 | Philippe Sauvage | Chief Financial Officer | Derivative Exercise and Sale | -47,668 | $2.17–6.01 |
| 2026-06-08 | Robert Mashal | Director | Open Market Acquisition | +25,000 | $4.73 |
| 2026-05-20 | Kathryn Falberg | Independent Director | Other Derivative Acquisition | +123,397 | $4.79 |
| 2026-05-20 | Kim Blickenstaff | Independent Director | Other Derivative Acquisition | +123,397 | $4.79 |
| 2026-05-20 | Robert Bazemore | Lead Independent Director | Other Derivative Acquisition | +123,397 | $4.79 |
| 2026-05-20 | Robert Mashal | Director | Other Derivative Acquisition | +123,397 | $4.79 |
| 2026-05-20 | William Vernon | Independent Director | Other Derivative Acquisition | +123,397 | $4.79 |
| 2026-05-20 | Xiangmin Cui | Director | Other Derivative Acquisition | +123,397 | $4.79 |
| 2026-04-16 | Kerry Wentworth | Chief Regulatory Officer | Derivative Exercise and Sale | -36,750 | $2.93–5.01 |
| 2026-04-16 | Dongfang Liu | -- | Derivative Exercise and Sale | -50,000 | $1.94–5.02 |
| 2026-04-05 | Kerry Wentworth | Chief Regulatory Officer | Derivative Exercise and Sale | -200,000 | $1.87–4.52 |
| 2026-02-26 | David Hung | Chief Executive Officer | Other Derivative Acquisition | +1,995,012 | $5.91 |
| 2026-02-26 | Kerry Wentworth | Chief Regulatory Officer | Other Derivative Acquisition | +748,130 | $5.91 |
| 2026-02-26 | Xiangmin Cui | Director | Other Derivative Acquisition | +76,923 | $5.91 |
| 2026-02-26 | Stacy Markel | Chief Human Resources Officer | Other Derivative Acquisition | +748,130 | $5.91 |
| 2026-02-26 | Gary Hattersley | Chief Scientific Officer | Other Derivative Acquisition | +748,130 | $5.91 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:33:56 · For reference only, not investment advice and not tailored to your situation.